Nami received SBIR Phase II support from NCI
Nami Therapeutics Corp. received a $2M SBIR Phase II grant from National Institute of Health National Cancer Institute (NCI) to translate their nanoparticle-based radiopharmaceutical product to the clinic for treating metastatic ovarian cancer. The Nami team is fully committed to using novel nanotechnologies to improve cancer treatment and provide patients another chance of a cancer free life.
作者
admin
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam viverra euismod odio, gravida pellentesque urna varius vitae. Sed dui lorem, adipiscing in adipiscing et, interdum nec metus. Mauris ultricies, justo eu convallis placerat, felis enim ornare nisi, vitae mattis nulla ante id dui.